stockrow
Saturday 7 November 2026
Export NMTC’s income statement to Excel — free account
NeuroOne Medical Technologies Corporation
NMTC Healthcare Medical Devices
NeuroOne Medical Technologies Corporation’s revenue for fiscal 2025 (year ended September 2025) was $9.1 million, up 163.5% from fiscal 2024.
- Revenue
- +16.3%
- EPS
- −27.8%
- Free cash flow
- +26.9%
Quarter to June 2026, against a year earlier
0.85
0.01
−1.16%
Follow NMTC
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.78 | 4.30 | 4.38 | 3.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.34) | (29.76) | (12.25) | (23.38) | |
P/B ratio |
6.99 | 7.79 | 5.96 | 5.04 | |
Price to Tangible BV |
7.04 | 7.84 | 6.00 | 5.08 | |
EV/Sales |
2.56 | 4.00 | 3.97 | 3.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.44) | (4.94) | (5.62) | (10.26) | |
EV/FCF |
(3.39) | (4.85) | (5.53) | (9.97) | |
Quick Ratio |
1.54 | 2.78 | 4.95 | 3.40 | |
Current Ratio |
2.84 | 4.21 | 6.41 | 4.44 | |
Net Debt/EBITDA |
0.86 | 1.20 | 2.17 | 5.03 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.11 | 1.53 | 1.16 | 1.13 | |
Operating CF/Net income |
0.54 | 0.56 | 2.17 | 0.94 | |
Capex/Depreciation |
(0.42) | (0.64) | (0.62) | (0.16) | |
Research and Development Expense of Revenue |
72.23% | 78.84% | 48.04% | 40.79% | |
Selling, General and Administrative Expense of Revenue |
110.58% | 103.08% | 65.18% | 65.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.88% | 18.37% | 12.42% | 13.08% | |
Graham Net Nets |
0.13 | 0.12 | 0.15 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(30.59%) | (18.88%) | (22.42%) | (9.01%) | |
Free Cash Flow Yield |
(27.20%) | (19.14%) | (16.40%) | (8.18%) | |
Revenue per Share |
0.23 | 0.22 | 0.34 | 0.41 | |
Operating CF per Share |
(0.12) | (0.16) | (0.37) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.16) | (0.38) | (0.23) | |
Cash per Share |
0.24 | 0.33 | 0.42 | 0.98 | |
Shareholders Equity per Share |
0.43 | 0.60 | 0.76 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.43 | 0.60 | 0.76 | 1.06 | |
Free Cash Flow |
(1.10) | (1.37) | (3.16) | (1.54) | |
Working Capital |
3.75 | 5.42 | 6.81 | 7.92 | |
Capital Expenditures |
(0.02) | (0.04) | (0.04) | (0.01) | |
Net Current Asset Value |
3.37 | 4.62 | 5.89 | 6.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.71 | 2.13 | 1.42 | 0.84 | |
Average Payables |
0.69 | 0.92 | 0.65 | 1.02 | |
Average Inventory |
2.09 | 1.97 | 1.80 | 2.43 | |
Average Assets |
8.50 | 6.01 | 7.54 | 8.08 | |
Average Common Equity |
5.97 | 3.10 | 4.67 | 3.95 |
Columns are period end dates · fundamentals updated 26 Oct 2026